Taysha Gene Therapies, Inc.
Recent Filings
All 377 filings →| Form | Description | Date |
|---|---|---|
| 8-K | 8-K | Mar 19, 2026 |
| 10-K | 10-K | Mar 19, 2026 |
| 144 | — | Feb 27, 2026 |
| SCHEDULE 13G | — | Feb 17, 2026 |
| SCHEDULE 13G/A | — | Feb 17, 2026 |
| 4 | — | Feb 6, 2026 |
| SCHEDULE 13G/A | — | Feb 5, 2026 |
| 144 | — | Feb 4, 2026 |
| 144 | — | Feb 4, 2026 |
| 144 | — | Feb 4, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Date |
|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | Sale | 200,000 @ $3.23 | Sep 10, 2025 |
| Nagendran Sukumar | President and Head of R&D | Sale | 57,054 @ $2.85 | Aug 21, 2025 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Sale | 54,491 @ $2.85 | Aug 21, 2025 |
| Stalfort John A III | — | Award / Grant | 56,623 | Jun 2, 2025 |
| Donenberg Phillip B. | — | Award / Grant | 56,623 | Jun 2, 2025 |
| Long Alison S | — | Award / Grant | 56,623 | Jun 2, 2025 |
| Sepp-Lorenzino Laura | — | Award / Grant | 56,623 | Jun 2, 2025 |
| Manning Paul B | — | Purchase | 750,000 @ $2.75 | May 30, 2025 |
| Nolan Sean P. | Chief Executive Officer | Award / Grant | 892,500 | Jan 2, 2025 |
| Nagendran Sukumar | President and Head of R&D | Award / Grant | 324,500 | Jan 2, 2025 |